Piśmiennictwo

1. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, Betz JM, Sempos CT, Picciano MF: Dietary supplement use in the United States, 2003–2006. J Nutr 141:261–266, 2011

2. Nathin RL, Barnes PM, Stussman BJ, Bloom B: Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. National Health Statistics Report no 18. Hyattsville, Md., National Center for Health Statistics, 2009

3. Kennedy J: Herb and supplement use in the U.S. adult population. Clin Ther 27:1847– 1858, 2005

4. Garrow D, Egede LE: Association between complementary and alternative medicine use, preventive care practices, and use of conventional medical services among adults with diabetes. Diabetes Care 29:15–19, 2006

5. Dannemann K, Hecker W, Haberland H, Herbst A, Galler A, Schafer T, Brahler E, Kiess W, Kapellen TM: Use of complementary and alternative medicine in children with type 1 diabetes mellitus: prevalence, patterns of use, and costs. Pediatr Diabetes 9:228–235, 2008

6. Villa-Caballero L, Morello CM, Chynoweth ME, Prieto-Rosinol A, Polonsky WH, Palinkas LA, Edelman SV: Ethnic differences in complementary and alternative medicine use among patients with diabetes. Complement Ther Med 18:241–248, 2010

7. Odegard PS, Janci MM, Foepppel MP, Beach JR, Trence DL: Prevalence and correlates of dietary supplement use in individuals with diabetes mellitus at an academic diabetes care clinic. Diabetes Educ 37:419–425, 2011

8. Palinkas LB, Kabongo ML, San Diego Unified Practice Research in Family Medicine Network: The use of complementary and alternative medicine by primary care patients: a SURF*NET study. J Fam Pract 49:1121– 1130, 2000

9. Nahin RL, Byrd-Clark D, Stussman BJ, Kalyanaraman N: Disease severity is associated with the use of complementary medicine to treat or manage type-2 diabetes: data from the 2002 and 2007 National Health Interview Survey. BMC Complement Altern Med 12:193, 2012 (doi: 10.1186/1472-6882-12-193)

10. Chang CLT, Lin Y, Bartolome AP, Chen Y-C, Chiu S-C, Yang W-C: Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. Evid Based Complement Altern Med Article ID 378657. Available from http://dx.doi. org/10.1155/2013/378657. Accessed 25 May 2013

11. Harel Z, Harel S, Waid R, Mamdani M, Bell CM: The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med 15:1–3, 2013

12. ConsumerReports.org: 10 surprising dangers of vitamins and supplements: Don’t assume they’re safe because they’re ‘all natural.’ Consumer Reports September 2012. Available from http://www.consumerreports. org/content/cro/en/consumer-reportsmagazine/ z2012/September/vitaminsSupplements. print.html. Accessed 25 May 2013

13. Jellin JM, Gregory PJ: Pharmacist’s Letter/ Prescriber’s Letter Natural Medicines Comprehensive Database. 13th ed. Stockton, Calif., Therapeutic Research Faculty, 2013

14. Head KA: Benfotiamine. Altern Med Rev 11:238–242, 2006

15. Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P: Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 49:220–224, 1999

16. Simeonov S, Pavlova M, Mitkov M, Mincheva L, Troey D: Therapeutic efficacy of „Milgamma” in patients with painful diabetic neuropathy. Folia Medica 39:5–10, 1997

17. Haupt E, Ledermann H, Kopcke W: Benfotiamine in the treatment of diabetic polyneuropathy: a three-week randomized, controlled pilot study (BEDIP Study). Int J Clin Pharmacol Ther 43:71–77, 2005

18. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG: Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 116:600–605, 2008

19. Stracke H: A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 104:311–316, 1996

20. Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, Hanssen KF: The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35:1095–1097, 2012

21. Ziegler D, Tesfaye S, Kempler P: Comment on: Fraser et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 35:1095–1097, 2012

22. Hammes H-P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299, 2003

23. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, Thornalley PJ: Highdose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomized, double-blind placebo-controlled study. Diabetologia 52:208–212, 2009

24. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ: A double-blind, randomized, placebo- controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33:1598–1601, 2010

25. Dong H, Wang N, Zhao L, Lu F: Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Evid Based Complement Alternat Med 591654, 2012 (doi:10.1155/2012/591654)

26. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G: Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93:2559–2565, 2008

27. Yin J, Xing H, Ye J: Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712–717, 2008

28. Zhang H, Wei J, Xue R, Wu J-D, Zhao W, Wang Z-Z, Wang S-K, Zhou Z-X, Song D-Q, Wang Y-M, Pan H-N, Kong W-J, Jiang J-D: Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59:285–292, 2010

29. Guo Y, Li F, Ma X, Cheng X, Zhou H, Klaassen CD: CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica 41:996–1005, 2011

30. Baker WL, Gutierrez-Williams G, White CM, Kluger J, Coleman CI: Effect of cinnamon on glucose control and lipid parameters. Diabetes Care 31:41–43, 2008

31. Crawford P: Effectiveness of cinnamon for lowering hemoglobin A1c in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med 22:507–512, 2009

32. Akilen R, Tsiami A, Devendra D, Robinson N: Glycated haemoglobin and blood pressurelowering effect of cinnamon in multi-ethnic type 2 diabetic patients in the UK: a randomized, placebo-controlled, double-blind clinical trial. Diabet Med 27:1159–1167, 2010

33. Leach MJ, Kumar S: Cinnamon for diabetes mellitus. Cochrane Database Syst Rev 9:CD007170, 2012 (doi:10.1002/14651858. CD007170.pub2)

34. Akilen R, Tsiami A, Devendra D, Robinson N: Cinnamon in glycaemic control: systematic review and meta analysis. Clin Nutr 31:609–615, 2012

35. Anderson RA, Broadhurst CL, Polansky MM, Schmidt WF, Khan A, Flanagan VP, Schoene NW, Graves DJ: Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem 52:65–70, 2004

36. Chase CK, McQueen CE: Cinnamon in diabetes mellitus. Am J Health-Syst Pharm 64:1033–1035, 2007

37. Kirkham S, Akilen R, Sharma S, Tsiami A: The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance. Diabetes Obes Metab 11:1100–1113, 2009

38. Kim SH, Huyn SH, Choung SY: Antidiabetic effect of cinnamon extract on blood glucose in db/db mice. J Ethnopharmacol 104:119–123, 2006

39. Rafehi H, Ververis K, Karagiannis TC: Controversies surrounding the clinical potential of cinnamon for the management of diabetes. Diabetes Obes Metab 14:493–499, 2012

40. Hlebowicz J, Darwiche G, Bjorgell, Almer L-O: Effect of cinnamon on post-prandial blood glucose, gastric emptying, and satiety in healthy subjects. Am J Clin Nutr 85:1552– 1556, 2007

41. Pepping J: Alternative therapies: coenzyme Q10. Am J Health-Syst Pharm 56:519–521, 1999

42. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ: Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19:535–554, 2010

43. Bonakdar RA, Guarneri E: Coenzyme Q10: Am Fam Phys 72:1065–1070, 2005

44. Littarru GP, Luca T: Clinical aspects of coenzyme Q10: an update. Nutrition 26:250– 254, 2010

45. Fotino AD, Thompson-Paul AM, Bazzano LA: Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr 97:268–275, 2013

46. Alehagen U, Johansson P, Bjornstedt M, Rosen A, Dahlstrom U: Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 176:1860–1866, 2013

47. Henriksen JE, Andersen CB, Hother- Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H: Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. Diabet Med 16:312–318, 1999

48. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56:1137–1142, 2002

49. Mezawa M, Takemoto M, Onishi S, Ishibashi R, Ishikawa T, Yamaga M, Fujimoto M, Okabe E, He P, Kobayashi K, Yokote K: The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors 38:416–421, 2012

50. Ganesan S, Ito MK: Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Metab Syndr Relat Disord 11:251–255, 2013

51. Hamilton SJ, Chew GT, Watts GF: Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 32:810–812, 2009

52. McKay DL, Chen CYO, Saltzman E, Blumberg J: Hibiscus Sabdariffa L. tea (Tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr 140:298–303, 2010

53. Hopkins AL, Lamm MG, Funk JL, Ritenbaugh C: Hibiscus sabdariffa L, in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies. Fitoterapia 85:84–94, 2013

54. Wahabi HA, Alansary LA, Al-Sabban AH, Glasziuo P: The effectiveness of Hibiscus sabdariffa in the treatment of hypertension: a systematic review. Phytomedicine 17:83–86, 2010

55. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M, Fatehi F, Noori- Shadkam M: The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes. J Hum Hypertens 23:48–54, 2009

56. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M, Fatehi F: Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. J Alt Compl Med 15:899–903, 2009

57. Ngamjarus C, Pattanittum P, Somboonporn C: Roselle for hypertension in adults. Cochrane Database Syst Rev 1:CD007894, 2010 (doi: 10.1002/14651858.CD007894. pub2)

58. Fakeye TO, Adegoke AO, Omoyeni OC, Famakinde AA: Effects of water extract of Hibiscus sabdariffa, Linn (Malvaceae) ‘Roselle” on excretion of a diclofenac formulation. Phytother Res 21:96–98, 2007

59. Ndu OO, Nworu CS, Ehiemere CO, Ndukwe NC, Ochiogu IS: Herb-drug interaction between the extract of Hibiscus sabdariffa L. and hydrocholorothiazide in experimental animals. J Med Food 14:640– 644, 2011

60. Kolawole JA, Maduenyi A: Effect of zobo drink (Hibiscus sabdariffa water extract) on the pharmacokinetics of acetaminophen in human volunteers. Eur J Drug Metab Pharmacokinet 29:25–29, 2004

61. Venkatesh S, Thilagavathi J, Shyam Sundar D: Anti-diabetic activity of flowers of Hibiscus rosasinensis. Fitoterapia 79:79–81, 2008

62. Andallu B, Suryakanham V, Srikanthi BL, Reddy GK: Effect of mulberry (Morus indica L) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes. Clin Chim Acta 314:47–53, 2001

63. Murata K, Yatsunami K, Fukuda E, Onodera S, Mizukami O, Hoshino G, Kamel T: Antihyperglycemic effects of propolis mixed with mulberry leaf extract on patients with type 2 diabetes. Altern Ther Health Med 10:78–79, 2004

64. Mudra M, Ercan-Fang N, Zhong L, Furne J, Levitt M: Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diabetes Care 30:1272–1274, 2007

65. Hansawasdi C, Kawabata J: α-Glucosidase inhibitory effect of mulberry (Morus alba) leaves on Caco-2. Fitoterapia 77:568–573, 2006

66. Taniguchi S, Asano N, Tomino F, Miwa I: Potentiation of glucose-induced insulin secretion by fagomine, a pseudo-sugar isolated from mulberry leaves. Horm Metab Res 30:679–683, 1998

67. Aggarwal BB: Targeting inflammationinduced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30:173–199, 2010

68. University of Maryland Medical System: Turmeric. Available from http://www.umm. edu/altmed/articles/turmeric-000277.htm. Accessed 25 May 2013

69. Wickenberg J, Ingemansson SL, Hlebowicz J: Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J 9:43–47, 2010

70. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S: Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35:2121–2127, 2012

71. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G: Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 45:365–370, 2011

72. Steigerwalt R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, Luzzi R, Togni S, Dugall M, Cesarone MR, Ippolito E, Errichi BM, Ledda A, Hosoi M, Corsi M: Meriva, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med 54 (1 Suppl. 4):11–16, 2012

73. Epstein J, Sanderon IR, MacDonald TT: Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103:1545–1557, 2010

74. Lekshmi PC, Arimboor R, Indulekha PS, Menon AN: Turmeric (Curcuma longa L.) volatile oil inhibits key enzymes linked to type 2 diabetes. Int J Food Sci Nutr 63:832–834, 2012

75. Maradana MR, Thomas R, O’Sullivan BJ: Targeted delivery of curcumin for treating type 2 diabetes. Mol Nutr Food Res 57:1550–1556, 2013

76. Takikawa M, Kurimoto Y, Tusda T: Curcumin stimulates glucagon-like peptide-1 secretion in GLUTag cells via Ca2+/calmodulin- dependent kinase II activation. Biochem Biophys Res Commun 435:165–170, 2013

77. Mitrou P, Raptis AE, Lambadiari V, Boutati E, Petsiou E, Spanoudi F, Papakonstantinou E, Maratou E, Economopoulos T, Dimitriadis G, Raptis SA: Vinegar decreases postprandial hyperglycemia in patients with type 1 diabetes. Diabetes Care 33:e27, 2010

78. Johnston CS, Steplewska I, Long CA, Harris LN, Ryals RH: Examination of the antiglycemic properties of vinegar in healthy adults. Ann Nutr Metab 56:74–79, 2010

79. Johnston CS, White AM, Kent SM: Preliminary evidence that regular vinegar ingestion favorably influences hemoglobin A1c values in individuals with type 2 diabetes mellitus. Diabetes Res Clin Pract 84:e15–e17, 2009

80. White AM, Johnston CS: Vinegar ingestion at bedtime moderates waking glucose concentrations in adults with well-controlled type 2 diabetes. Diabetes Care 30:2814–2815, 2007

81. Johnston CS, White AM, Kent SM: A preliminary evaluation of the safety and tolerance of medicinally ingested vinegar in individuals with type 2 diabetes. J Med Food 11:179–183, 2008

82. Hlebowicz J, Darwiche G, Bjorgell O, Almer L: Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes: a pilot study. BMC Gastroenterol 7:46, 2007

83. Wrenn K: The perils of vinegar and the Heimlich maneuver. Ann Emerg Med 47:207–208, 2006

84. Lhotta K, Hofle G, Gasser R, Finkenstedt G: Hypokalemia, hyperreninemia and osteoporosis in a patient ingesting large amounts of cider vinegar. Nephron 80:242–243, 1998

85. Birdee GS, Yeh G: Complementary and alternative medicine therapies for diabetes: a clinical review. Clinical Diabetes 28:147–153, 2010

86. Shane-McWhorter L: Dietary supplements for diabetes: an evaluation of commonly used products. Diabetes Spectrum 22:206–213, 2009